Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

The following table is representative of revenue and significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment (in thousands):


	Three Months Ended March 31,
	2026			2025
Revenues	$	563		$	197
Program expenses (1)
Clinical trial studies(1)		422			758
Manufacturing, RenovoCath		236			250
Other research and development expenses		57			127
Non-program expenses (2)		1,527			1,106
Personnel compensation and related expenses, including share-based compensation		1,789			1,067
Other segment items (3)		53			(691	)

Net loss	$	(3,521	)	$	(2,420	)

(1)

Includes external research expenses, clinical studies, manufacturing including manufacturing and non-recurring engineering costs, professional and consulting, regulatory, and trade shows for 2026.

(2)

Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, marketing expenses for 2026 and other office expenses.

(3)

Includes interest income and interest expense and gain recognized on the fair value of common stock warrant liability.

Major Customers

For the three months ended March 31, 2026 and 2025, five customers, Customers A, B, C, D and E, accounted for more 10% of the Company's total revenue. For the three months ended March 31, 2026, Customers A, B and C accounted for 27.2%, 15.2% and 13.6%, respectively. For the three months ended March 31, 2025, Customers A accounted for 34.8% and Customers D and E each accounted for 26.1%.